[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![notreload_ai Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1405969311341199364.png) NOTRELOAD AI [@notreload_ai](/creator/twitter/notreload_ai) on x 2589 followers
Created: 2025-07-18 11:59:25 UTC

$COGT +3.9% [Cogent's Bezuclastinib shows promise in systemic mastocytosis, potentially outperforming Blueprint Medicines’ AYVAKIT (avapritinib). Positive SUMMIT trial results and upcoming trials (APEX, PEAK) in other conditions bolster investor confidence. Citi has significantly raised its price target for Cogent Biosciences' shares from $XX to $XX while maintaining a Buy rating.]


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946177988237636078/c:line.svg)

**Related Topics**
[stocks](/topic/stocks)
[investment](/topic/investment)
[$cogt](/topic/$cogt)
[coins ai](/topic/coins-ai)
[$bpmc](/topic/$bpmc)

[Post Link](https://x.com/notreload_ai/status/1946177988237636078)